Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Draper

Showing results (391-400 of 404) with videos related to

Pageof 41
Sort By:
Medrxiv : the Preprint Server for Health Sciences|June 6, 2022
Impact of a blood-stage vaccine on <i>Plasmodium vivax</i> malariaMimi M Hou, Jordan R Barrett, Yrene Themistocleous, et al.
JCO Precision Oncology|July 12, 2021
Prospective Statewide Study of Universal Screening for Hereditary Colorectal Cancer: The Ohio Colorectal Cancer Prevention InitiativeRachel Pearlman, Wendy L Frankel, Benjamin J Swanson, et al.
Cell Reports. Medicine|July 17, 2024
Preclinical development of a stabilized RH5 virus-like particle vaccine that induces improved antimalarial antibodiesLloyd D W King, David Pulido, Jordan R Barrett, et al.
Science Translational Medicine|July 12, 2023
Vaccination with <i>Plasmodium vivax</i> Duffy-binding protein inhibits parasite growth during controlled human malaria infectionMimi M Hou, Jordan R Barrett, Yrene Themistocleous, et al.
JAMA Oncology|December 16, 2016
Prevalence and Spectrum of Germline Cancer Susceptibility Gene Mutations Among Patients With Early-Onset Colorectal CancerRachel Pearlman, Wendy L Frankel, Benjamin Swanson, et al.
The Journal of Infectious Diseases|February 25, 2016
Demonstration of the Blood-Stage Plasmodium falciparum Controlled Human Malaria Infection Model to Assess Efficacy of the P. falciparum Apical Membrane Antigen 1 Vaccine, FMP2.1/AS01Ruth O Payne, Kathryn H Milne, Sean C Elias, et al.
Cell|July 26, 2024
Analysis of the diverse antigenic landscape of the malaria protein RH5 identifies a potent vaccine-induced human public antibody clonotypeJordan R Barrett, Dimitra Pipini, Nathan D Wright, et al.
Nature Communications|September 25, 2025
Development of clinical immunity to Plasmodium vivax following repeat controlled human malaria infectionMimi M Hou, Adam C Harding, Natalie M Barber, et al.
The Lancet. Infectious Diseases|June 16, 2024
Blood-stage malaria vaccine candidate RH5.1/Matrix-M in healthy Tanzanian adults and children; an open-label, non-randomised, first-in-human, single-centre, phase 1b trialSarah E Silk, Wilmina F Kalinga, Jo Salkeld, et al.
JCI Insight|October 5, 2021
Controlled human malaria infection with a clone of Plasmodium vivax with high-quality genome assemblyAngela M Minassian, Yrene Themistocleous, Sarah E Silk, et al.
Pageof 41

Showing results (391-400 of 404) with videos related to

Sort By:
Pageof 41
Medrxiv : the Preprint Server for Health Sciences|June 6, 2022
Impact of a blood-stage vaccine on <i>Plasmodium vivax</i> malariaMimi M Hou, Jordan R Barrett, Yrene Themistocleous, et al.
JCO Precision Oncology|July 12, 2021
Prospective Statewide Study of Universal Screening for Hereditary Colorectal Cancer: The Ohio Colorectal Cancer Prevention InitiativeRachel Pearlman, Wendy L Frankel, Benjamin J Swanson, et al.
Cell Reports. Medicine|July 17, 2024
Preclinical development of a stabilized RH5 virus-like particle vaccine that induces improved antimalarial antibodiesLloyd D W King, David Pulido, Jordan R Barrett, et al.
Science Translational Medicine|July 12, 2023
Vaccination with <i>Plasmodium vivax</i> Duffy-binding protein inhibits parasite growth during controlled human malaria infectionMimi M Hou, Jordan R Barrett, Yrene Themistocleous, et al.
JAMA Oncology|December 16, 2016
Prevalence and Spectrum of Germline Cancer Susceptibility Gene Mutations Among Patients With Early-Onset Colorectal CancerRachel Pearlman, Wendy L Frankel, Benjamin Swanson, et al.
The Journal of Infectious Diseases|February 25, 2016
Demonstration of the Blood-Stage Plasmodium falciparum Controlled Human Malaria Infection Model to Assess Efficacy of the P. falciparum Apical Membrane Antigen 1 Vaccine, FMP2.1/AS01Ruth O Payne, Kathryn H Milne, Sean C Elias, et al.
Cell|July 26, 2024
Analysis of the diverse antigenic landscape of the malaria protein RH5 identifies a potent vaccine-induced human public antibody clonotypeJordan R Barrett, Dimitra Pipini, Nathan D Wright, et al.
Nature Communications|September 25, 2025
Development of clinical immunity to Plasmodium vivax following repeat controlled human malaria infectionMimi M Hou, Adam C Harding, Natalie M Barber, et al.
The Lancet. Infectious Diseases|June 16, 2024
Blood-stage malaria vaccine candidate RH5.1/Matrix-M in healthy Tanzanian adults and children; an open-label, non-randomised, first-in-human, single-centre, phase 1b trialSarah E Silk, Wilmina F Kalinga, Jo Salkeld, et al.
JCI Insight|October 5, 2021
Controlled human malaria infection with a clone of Plasmodium vivax with high-quality genome assemblyAngela M Minassian, Yrene Themistocleous, Sarah E Silk, et al.
Pageof 41